Home blood pressure monitoring and changes in plasma catecholamines during once or twice daily treatment with atenolol in patients with mild hypertension

Australian and New Zealand Journal of Medicine
B P McGrathR Cooper

Abstract

1. The effects of atenolol on diurnal blood pressure control, heart rate and plasma catecholamines were studied in nine hypertensives, six of whom also received diuretics. The patients completed a double-blind trial in which the effects of once and twice daily administration of atenolol were compared with placebo. 2. Atenolol (100 mg) given once a day produced significant reduction in diurnal blood pressures recorded at home but the effect was slightly less than either 50 mg given twice a day or 200 mg once a day. 3. Effects on heart rate and blood pressure were seen within 36 hours of the first dose, and were near maximal at 72 hours. After cessation of the drug, mean resting heart rate increased gradually and reached pre-treatment levels five days later, suggesting strong tissue binding of atenolol. Blood pressure increased more slowly over 8--10 days. 4. Plasma noradrenaline levels were increased at rest with atenolol. This argues strongly against the antihypertensive effect of atenolol being due to a reduction of sympathetic nerve activity. 5. Once daily administration of atenolol in this group of patients with mild hypertension produced satisfactory diurnal blood pressure control and beta blockade without "rebound" hyperte...Continue Reading

References

Oct 1, 1977·British Journal of Clinical Pharmacology·H HörtnaglD G Grahame-Smith
Apr 1, 1975·Seminars in Nuclear Medicine·J E Sealey, J H Laragh
May 17, 1975·British Medical Journal·L HanssonA Westerlund
Jun 1, 1978·Kidney International·G W ThomasK M Yeates
Apr 24, 1976·British Medical Journal·A P Douglas-Jones, J M Cruickshank
May 1, 1976·Clinical Pharmacology and Therapeutics·M G MyersC T Dollery
Jan 1, 1976·The Journal of International Medical Research·A M HarrisJ A Tweed
Oct 18, 1975·British Medical Journal·J C PetrieJ A Lewis
Jun 16, 1973·Lancet·L W FlemingW K Stewart
Nov 1, 1974·Annals of Internal Medicine·E L AldermanD C Harrison

Citations

Jan 1, 1986·European Journal of Clinical Pharmacology·R VandongenP Rogers
Oct 18, 2000·Pharmacology & Therapeutics·R A Altschuld, G E Billman
May 1, 1982·Clinical Cardiology·D T O'Connor, R A Preston
Mar 20, 2009·International Urology and Nephrology·Yasmin PashaDavid Goldsmith
Aug 1, 1986·European Journal of Clinical Microbiology·K Tunér, C E Nord
Feb 8, 2014·The Cochrane Database of Systematic Reviews·Edgardo AbalosD Wilhelm Steyn

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Nodding Syndrome

Nodding Syndrome is a neurological and epileptiform disorder characterized by psychomotor, mental, and growth retardation. Discover the latest research on Nodding Syndrome here.

LRRK2 & Microtubules

Mutations in the LRRK2 gene are risk-factors for developing Parkinson’s disease (PD). LRRK2 mutations in PD have been shown to enhance its association with microtubules. Here is the latest research.